key: cord-1032429-tqrn83il
authors: Banerji, Aleena; Wolfson, Anna R.; Wickner, Paige G.; Cogan, Amelia S.; McMahon, Aubree E.; Saff, Rebecca; Robinson, Lacey B.; Phillips, Elizabeth; Blumenthal, Kimberly G.
title: COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach
date: 2021-04-15
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.03.053
sha: b1c6eb6352234e4c2e83997da12dbf7636c8561e
doc_id: 1032429
cord_uid: tqrn83il

nan

None. herpes zoster vaccine (9.6 per million). 4 However, prospective cohort data from over 60,000 55 Mass General Brigham (MGB) employees found a higher incidence rate of anaphylaxis to the 56 mRNA COVID-19 vaccines at 2.47 per 10,000 vaccinations. 7 The marked difference in observed 57 incidence rates likely relates to incomplete CDC capture of cases, although the MGB cohort may 58 have a higher rate than some US populations because of demographic or geographic effects. There are currently no efficacy data on this "mix and match" approach and we do not know the 100 long-term durability of protection from any of the current COVID-19 vaccines. 

COVID-19 Dashboard by the Center for Systems Science and 190

Accessed March 25 th

mRNA Vaccines to Prevent COVID-19 Disease and Reported 194

Allergic Reactions: Current Evidence and Suggested Approach

Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States

States Department of Health and Human Services

Vaccine Safety Monitoring -United States

Response Team; Food and Drug Administration

Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

MMWR Morb Mortal Wkly Rep

Reports of Anaphylaxis After Receipt of mRNA COVID-19

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers): Emergency Use 211

Authorization (EUA) of the Janssen Covid-19 Vaccine to Prevent Coronavirus Disease

J&J Says Two Trial Participants Had Severe Allergic Reactions After Getting Covid

Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have

Vaccines Currently Authorized in the United States United States Department of Health and Human

Accessed March 24 th

The authors thank many colleagues in the Mass General Brigham health system for the design 148 and implementation of the COVID-19 vaccination program, including Paul D. Biddinger, MD,